= Emerging. More than 5 years before clinical availability. (19.79%)
= Expected to be clinically available in 1 to 4 years. (37.97%)
= Clinically available now. (42.25%)
MSACL 2022 : Liao

MSACL 2022 Abstract

Self-Classified Topic Area(s): Tox / TDM / Endocrine > none > none

Podium Presentation in De Anza 2 on Thursday at 15:55 (Chair: Melissa Budelier / Imir Metushi)

Opiate Drug Testing Does Not have to be a “pain in the MLS”: How a Second-generation LC-MS/MS Assay Improved Workflow for Drug Testing and Sign-out

Hsuan-Chieh (Joyce) Liao, Thomas J. Laha, Patrick C Mathias, Geoffrey S. Baird, Andrew N. Hoofnagle*
Laboratory Medicine and Pathology, University of Washington, Seattle, WA

Hsuan-Chieh (Joyce) Liao (Presenter)
University of Washington

Presenter Bio: Dr. Liao has more than ten years of clinical and management experience in the laboratory medicine and newborn screening center. She was a Medical Laboratory Scientist who trained in Taiwan. After obtaining her PhD in Clinical Medicine, she completed postdoctoral fellowship training in Clinical Chemistry at the University of Washington and Seattle Children Hospital. She is board certified as a Clinical Chemist by both the American Board of Clinical Chemistry and National Registry of Certified Chemists. She continues to focus on translation of the analytical power of mass spectrometry to real clinical applications.

Abstract

INTRODUCTION
The widespread use of opioid drugs for nonmedical or recreational purposes has contributed to escalating rates of addiction, drug overdoses, and drug-related deaths. As a result, simple and efficient urine drug testing is critical for clinicians to monitor compliance and to prevent medication diversion. LC-MS/MS provides superior sensitivity and specificity while providing detailed information on the presence of individual drugs and their metabolites. However, the complexities of workflow and instrument operation, along with the requirements of highly trained personnel to troubleshoot and interpret results, present major challenges to clinical laboratories.

OBJECTIVE
In this study, we leveraged upgraded instrumentation to develop and validate a new LC-MS/MS assay allowing us to simplify and improve workflows and data analysis.

METHODS
Urine specimens were centrifuged and the resulting supernatants were diluted with internal standards by a robotic liquid handler. Sixteen opioids were quantified by using gravimetrically-prepared calibrators, while tramadol and 7 glucuronide-metabolites were detected qualitatively with a single-point cut-off calibrator. The assay was developed and validated simultaneously on two identical Waters Acquity UPLC/Xevo TQXS LC-MS/MS systems. The assay performance was evaluated following CLSI C62-A guidelines and the results were correlated to a previous version of the assay using two Waters Acquity UPLC/Xevo TQMS systems. An in-house developed web-based software application was implemented for quality assurance and for simplifying pathologist review and interpretation.

RESULTS
By modifying the chromatographic gradient, isobaric oxycodone and oxycodone metabolite interferences in the codeine and codeine-6 glucuronide transitions were well-resolved compared to the previous assay. The upgraded mass spectrometers provided better sensitivity and greater dynamic range, which enabled us to expand the analytical measurement ranges with a single injection of one diluted sample. Among all the analytes, intra- and inter-assay imprecision was less than 10% and carryover was less than 0.01%. The lower limit of the measuring interval was less than 5, 0.1, 20, and 200 ng/mL for most opioids, fentanyl, tramadol and opioid glucuronides, and ethyl glucuronide, respectively. The correlation coefficients were >0.95 for quantitative analytes compared to the previous assay. Acceptable limits of relative retention times, ion ratios, and internal standard peak areas were established during validation and included in the web-based software application for quality assurance purposes.

CONCLUSIONS
A simplified "dilute-and-shoot" LC-MS/MS opiate assay was developed and validated. The improved analysis maintains clinical requirements while eliminating isobaric interferences, reducing turnaround time, and doubling testing capacity. The combination of analytical and workflow improvements demonstrated in this work lay the groundwork to improve the efficiency of other complexes LC-MS/MS assays in our laboratory.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no